Abstract
From the perspective of targeting factors, iron acetylacetonate and nickel acetylacetonate were used as major materials, and oleylamine was used as a solvent. Through thermal decomposition, the uniformly distributed nanoparticle FeNi3 was obtained. Then, the α-methyltryptophan (AMT) was used to modify FeNi3, thereby the material (FeNi3-AMT) would be biocompatible. The prepared material was used as a targeting factor to explore whether it could target the epileptogenic focus in temporal lobe epilepsy model rats. In the experiment, the animal models of temporal lobe epilepsy were constructed by using the lithium chloride-pirocarpine method. According to the injection of the nuclear magnetic factor, the models were divided into the FeNi3 group, the FeNi3-AMT group, and the saline group. The model rats received intravenous injections 48 hours after the onset of epilepsy. The activity of the epileptic seizure sites before and after injection, the penetration of nanoparticles, and the toxic and side effects of the material were compared. The results showed that the rat models of temporal lobe epilepsy were successfully constructed (the success rate was more than 85%). Meanwhile, the epilepsy lesions of the rat models added with nanoparticles were darker (P < 0.05). The staining of rat brain sections confirmed the distribution of iron particles. In the FeNi3-AMT group, there were more iron particles distributed (P < 0.05). In addition, various abnormal neurons appeared in the hippocampus of the three groups, and there was no significant difference between the different groups (P < 0.05). There was no significant difference in the number of positive neurons in the CA3 region of the brain between different groups (P < 0.05). However, the imaging effect based on FeNi3-AMT was more prominent (P < 0.05), which confirmed that the FeNi3-AMT group had better targeting location effects. The study confirmed that the iron nano alloy particle material had excellent application values in the localization of temporal lobe epilepsy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.